J., Mezquita-Raya, P., Carretero-Gmez, J., Castro, A., Cebrin-Cuenca, A., de Torres-Snchez, A., Garcia-de-Lucas, M
B., and Mootha, V
Evidence-based off-label use: A doctor prescribes semaglutide for obesity-related complications even at a slightly lower BMI threshold than official labeling, based on published trial data and the patients overall risk profile
Rybelsus has a higher peak nausea rate (25-35% vs 20-25%) due to daily dosing and the gastrointestinal absorption process
Since Mounjaro acts on two pathways, it tends to have superior outcomes in both diabetes and weight control than Ozempic
The difference between utilization management that works and one that doesn't comes down to how it's designed: Prior authorization should be based on clinical evidence, not designed to protect rebate-generating drugs Step therapy protocols need to reflect current treatment guidelines and be reviewed regularly A well-managed appeals process catches inappropriate denials before they become care gaps Clinical pharmacist oversight makes the difference between utilization management that helps and one that harms 3
